

HAB HIV Core Clinical Performance Measures: Adult/Adolescent Clients Group 2



Performance Measure: Hepatitis C Screening		OPR-Related Measure: Yes www.hrsa.gov/performance/mesures.htm																					
Percentage of clients for whom Hepatitis C (HCV) screening was performed at least once since the diagnosis of HIV infection																							
Numerator:	Number of HIV-infected clients who have documented HCV status in chart ¹																						
Denominator:	Number of HIV-infected clients who had a medical visit with a provider with prescribing privileges ² at least once in the measurement year																						
Patient Exclusions:	None																						
Data Element:	1. Is the client HIV-infected? (Y/N) a. If yes, is there documentation of the client's Hepatitis C status in the medical record? (Y/N)																						
Data Sources:	<ul style="list-style-type: none"> • Ryan White Program Data Report, Section 5, Items 42 and 48 may provide data useful in establishing a baseline for this performance measure • Electronic Medical Record/Electronic Health Record • CAREWare, Lab Tracker, or other electronic data base • HIVQUAL reports on this measure for grantee under review • Medical record data abstraction by grantee of a sample of records 																						
National Goals, Targets, or Benchmarks for Comparison	IHI Goal: 95% ³ National HIVQUAL Performance Data ⁴ <table border="1" style="width: 100%; border-collapse: collapse; text-align: center;"> <thead> <tr> <th></th> <th>2003</th> <th>2004</th> <th>2005</th> <th>2006</th> </tr> </thead> <tbody> <tr> <td>Top 10%</td> <td>100%</td> <td>100%</td> <td>100%</td> <td>100%</td> </tr> <tr> <td>Top 25%</td> <td>99.4%</td> <td>100%</td> <td>100%</td> <td>100%</td> </tr> <tr> <td>Mean*</td> <td>86.2%</td> <td>88.8%</td> <td>90.5%</td> <td>90.9%</td> </tr> </tbody> </table> <small>*from HAB data base</small>				2003	2004	2005	2006	Top 10%	100%	100%	100%	100%	Top 25%	99.4%	100%	100%	100%	Mean*	86.2%	88.8%	90.5%	90.9%
	2003	2004	2005	2006																			
Top 10%	100%	100%	100%	100%																			
Top 25%	99.4%	100%	100%	100%																			
Mean*	86.2%	88.8%	90.5%	90.9%																			
Outcome Measures for Consideration:	<ul style="list-style-type: none"> ○ Hepatitis C- related mortality rates in the clinic population 																						
Basis for Selection and Placement in Group 2:																							
<p>Chronic hepatitis C infection is common in persons with HIV infection, and although it is a source of substantial morbidity and mortality, it may be amenable to treatment. HIV/ hepatitis C co-infection may predispose HIV-infected patients to liver toxicity from HAART⁵ and HCV treatment may exacerbate the side effects of some ARV medications.⁶</p> <p>Measure reflects important aspect of care that impacts HIV-related morbidity and focuses on treatment decisions that affect a sizable population. Measure has a strong evidence base supporting the use.</p>																							
US Public Health Guidelines:																							

HAB HIV Core Clinical Performance Measures: Adult/Adolescent Clients Group 2



“All HIV-infected patients should be screened for HCV infection”⁷ (6/14/02)

References/Notes:

¹Unless there is concern about ongoing exposure (e.g., via active injection drug use), annual re-screening is not generally recommended.

²A “provider with prescribing privileges” is a health care professional who is certified in their jurisdiction to prescribe ARV therapy.

³IHI Measure reads, “Percent of Patients/Clients with Known Hepatitis C Status”

(<http://www.ihf.org/IHI/Topics/HIVAIDS/HIVDiseaseGeneral/Measures/PercentofPatientsClientswithKnownHepatitisCStatus.htm>)

⁴(<http://www.hivguidelines.org/admin/files/qoc/hivqual/proj%20info/HQNatlAggScrs3Yrs.pdf>)

⁵AIDS Institute, New York State Department of Health. Criteria for the Medical Care of Adults with HIV Infection, Hepatitis C Virus Updated September 2004 [*Text taken from the NYSDOH AI publication - "Criteria for the Medical Care of Adults with HIV Infection"*]

(http://www.hivguidelines.org/public_html/hep-c/hepc.pdf)

⁶Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents

(<http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf>)

⁷Centers for Disease Control and Prevention. Guidelines for Preventing Opportunistic Infections Among HIV-Infected Persons — 2002 Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR 2002;51(No. RR-8) (<http://www.cdc.gov/mmwr/PDF/rr/rr5108.pdf> or <http://aidsinfo.nih.gov/ContentFiles/OIpreventionGL.pdf>)